Prostate Cancer - Results from #220

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs. September 23, 2024

Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction. September 23, 2024

Beyond Medical Bills: The Indirect Costs of Prostate Cancer. September 23, 2024

A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study. September 23, 2024

Stereotactic radiotherapy for localized prostate cancer: 10-year outcomes from three prospective trials. September 20, 2024

Lipid Metabolism Modulatory Cisplatin Prodrug Sensitizes Resistant Prostate Cancer toward Androgen Deprivation Therapy. September 20, 2024

Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial. September 20, 2024

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. September 20, 2024

Secondary Cancer in Prostate Cancer Patients Treated With Advanced External Beam Radiation Therapy. September 20, 2024

A Common Culprit Drives Prostate Cancer Progression September 19, 2024

The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells. September 19, 2024

Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. September 19, 2024

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201). September 19, 2024

Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. September 19, 2024

Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project. September 19, 2024

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis. September 19, 2024

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. September 19, 2024

Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. September 19, 2024

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. September 19, 2024

Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. September 19, 2024

Page 12 of 1436